Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia

Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bottiglieri F, Modica R, de Cicco F, Minotta R, Faggiano A,

Keywords: gastric, neuroendocrine, type1, type3, metastases,

#2809 Sporadic Neuroendocrine Neoplasms in Young Adult Patients: Natural History, Prognosis and Management

Introduction: Data specific to sporadic neuroendocrine neoplasms (NEN) in young adult patients (pts) are limited due to its rare occurrence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Altieri B

Authors: Altieri B, Modica R, Bottiglieri F, de Cicco F, Faggiano A,

Keywords: neuroendocrine neoplasms, young patients, age, natural history, treatment, prognosis,

#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study

Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Massironi S

Authors: Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A,

Keywords: GEP-NEN, Second primary neoplasm (PMN), Overall survival (OS),

#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study

Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Faggiano A, Di Maio S, Tafuto S, Mocerino C, Di Sarno A,

Keywords: neuroendocrine tumor, medical therapy, sequence of treatments,

#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,

Abstract Submissions for 2024

Abstract submissions for 2024 are now closed; all submitted abstracts are currently being reviewed by the abstract reviewing committee.


The 21st Annual ENETS Conference in 2024 provides the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Conferences in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.